RFK Jr., what are you waiting on at HHS? You Makary, you look clueless on podium but this is your chance to cut the 'deer in the headlight look', step up now and BAN outright Depo-Provera! Research

evidence points to dramatic risk as birth control drug for women, RFK Jr. must pull this Pfizer drug NOW, no games like that being played with Malone Pfizer etc. mRNA vaccine 2.43 (95% CI, 1.77-3.33)

critical photo above as Cassidy reads FDA’s Makary riot act telling him para ‘don’t you dare phuck with the vaccines or mRNA Malone Pfizer Bourla Bancel Moderna Sahin BioNTech Weissman et al. shots, off limits to you, go talk about Tylenol and other misdirection oddities and leave the game to the big dogs, all I seek is for you is to keep quiet, remember, ‘less’ talking from you is ‘more’ talking from you’, capish’?

Back to the matter at hand on risk of brain tumors using Depo-Provera:

dramatic elevation of risk of meningioma, ‘a relative risk of 2.43 (95% CI, 1.77-3.33) for meningioma diagnosis compared with controls’…a 143% increase in risk…Pfizer has gotten away with murder with this injectable birth-control drug…due to heightened risk of brain tumors.

Over to you Bobby Jr., I have faith in you!

‘The number needed to harm for the depot medroxyprogesterone acetate was 1152 patients and 3020 patients for oral medroxyprogesterone acetate.’

See study here:

Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US

1. Tianqi Xiao, MD^1,2; Pranav Kumar, BA^1,2; Mina Lobbous, MD, MSPH^2,3

2. et al

‘Design, Setting, and Participants This retrospective population-based cohort study used data from TriNetX, a US national database of 68 health care organizations. Data were analyzed from December 2004 to December 2024. The incidence of meningioma diagnosis was compared between treatment groups through propensity-score matched analyses. Participants included a sample of females with use of only 1 of the following progestins/contraceptives: depot medroxyprogesterone acetate, oral medroxyprogesterone acetate, combined oral contraceptives, intrauterine devices, progestin only pills, or subdermal implantable contraceptive. The control group included females without use of these hormonal treatments. Of the 118 289 082 total patients in TriNetX at the time of analysis, 61 588 239 patients were female and eligible.

Exposures Patients were defined using diagnostic codes from the International Classification of Diseases, Current Procedural Terminology, and RxNorm codes within TriNetX.

Main Outcome and Measure The main outcome was meningioma diagnosis. Relative risks and number needed to harm were calculated.

Results There were 10 425 438 patients that met inclusion criteria with a mean age of 33.4 years at inclusion. After propensity score matching, 88 667 patients with mean age of 26.2 years at inclusion were in the depot medroxyprogesterone acetate group.

Use of depot medroxyprogesterone acetate had a relative risk of 2.43 (95% CI, 1.77-3.33) for meningioma diagnosis compared with controls. Notably, this risk was confined for patients with longer than 4 years of exposure or starting the prescription at ages older than 31 years. Oral medroxyprogesterone acetate had increased relative risk of 1.18 (95% CI, 1.10-1.27) compared with controls. No increased risk of meningioma diagnosis was found with any other contraceptive. The number needed to harm for the depot medroxyprogesterone acetate was 1152 patients and 3020 patients for oral medroxyprogesterone acetate.

Conclusions and Relevance In this study, women receiving depot medroxyprogesterone acetate had a greater relative risk of subsequent meningioma diagnosis, especially with prolonged exposures and starting the medication at older ages. The high number needed to harm suggests low clinical risk overall.’

___

You must not wait for another catastrophic crisis (at times manufactured but we are prevented from making our own basic personal decisions or accessing needed drugs and response tools) to catch you off-guard. We must take charge and be prepared today so that we can enjoy peace of mind tomorrow.

Enter the Wellness Company as a solution and a willing participant in the health care conversation. The Wellness Company, launched in 2022, offers health care, prescriptions, and supplements, all backed by research

The Wellness Company isn’t chasing profits — it’s trying to help people recover. While the government continues pushing vaccines, The Wellness Company is focusing on real solutions.

From telemedicine, prescriptions, memberships, and supplements, TWC is leading America with alternative choices to the traditional health care model.

Please consider support of a good PATRIOT company (in this PATRIOT economy) Drs. McCullough, Risch, Thorp, myself support (they are our sponsors), The Wellness Company; see the emergency preparation kit (key component being antibiotics you were denied by doctors, pharmacists, governments during the fraud COVID), first aid kit, travel emergency kit, contagion control kit etc. Please consider the SPIKE SUPPORT (spike protein DETOX dissolving spike from mRNA vaccine, this is critical to remove spike form the mRNA vaccine/and DNA viral vector) formula with NATTOKINASE as well as the triple formula (SPIKE SUPPORT, BROMELAIN, CIRCUMIN)

If you wish to give a donation to help me, you can at:

Zelle:

sr7283@gmail.com

Or Ko-Fi

Ko-fi.com/drpauleliasalexander

Or to my address at:

150 South 8th Street

Unit 170

Lewiston, New York

14092

Alternatively, please consider going from an UNPAID subscriber or follower to a PAID at $5 per month or $30 per year. This can provide me help. If this is not possible at this time, this is ok, please remain a subscriber for FREE and there is no difference between FREE and PAID. No restrictions.